NEUROBIOLOGY OF AGING
Verberk IMW, Hendriksen HMA, van Harten AC, Wesselman LMP, Verfaillie SCJ, van den Bosch KA, Slot RER, Prins ND, Scheltens P, Teunissen CE and Van der Flier WM.
Neurobiology of Aging. 2020.
DOI: https://doi.org/10.1016/j.neurobiolaging.2020.01.007
Plasma biomarkers are promising, easy-to-use prognostic tools in individuals with subjective cognitive decline (SCD). We aimed to investigate the relationships of baseline plasma amyloid beta (Abeta)42/Abeta40 and total Tau (tTau) with rate of cognitive decline, in comparison to relationships of baseline cerebrospinal fluid (CSF) Abeta42, tTau and phosphorylated tau181 (pTau) with rate of cognitive decline. We included 241 SCD subjects (age=61±9, 40% female, MMSE=28±2) with follow-up (average: 2±2 years, median visits: 3 (range: 1–11)) for re-evaluation of neuropsychological test performance (covering attention, memory, language and executive functioning domains). Using linear mixed models adjusted for age, gender and education, we found that lower plasma Abeta42/Abeta40 was associated with steeper rate of decline on tests assessing attention, memory and executive functioning, but not language. Lower CSF Abeta42 was associated with steeper decline on tests covering all domains. Plasma tTau was not associated with rate of cognitive decline, whereas CSF tTau and pTau were on multiple tests covering all domains. Associations for plasma amyloid and cognitive decline mirror those of CSF amyloid.
Neurology
Poster Background Developing effective therapies for glioblastoma (GBM) relies on robust preclinical animal models that enable detailed investigation of tumor biology, discovery of therapeutic targets, and evaluation of new treatment…
Oncology
Poster Background Ultrahigh-Plex Single-cell Spatial Phenotyping has revealed valuable insights into the tumor immune microenvironment (TiME) for biomarker discovery and stratification of clinical responses. Metabolic reprogramming is a key hallmark…
Neurology
Alzheimer’s Research and Therapy | August 26, 2024 Sampani K, Ness S, Tuz-Zahra F, Aytan N, Spurlock EE, Alluri S, Chen X, Siegel NH, Alosco ML, Xia W, Tripodis Y,…
Neurology
Poster The intersection of new therapeutic options for Alzheimer’s disease (AD), the emergence of accurate blood-based tests for AD, and the anticipated health system log jam for confirmatory diagnostic testing…
Neurology
Alzheimer’s & Dementia | August 3, 2024 Verberk IMW, Jutte J, Kingma MY, Vigneswaran S, Gouda MMTEE, van Engelen MP, Alcolea D, Arranz J, Fortea J, Lleó A, Chevalier C,…
Neurology
Journal of Lipid Research | August 2, 2024 Becktel DA, Frye JB, Le EH, Whitman SA, Schnellmann RG, Morrison HW, Doyle KP. J Lipid Res. 2024 https://doi.org/10.1016/j.jlr.2024.100614 Abstract Ischemic stroke…
